A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
- Study Title
- A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma
- Teva Identifier
- FpA-AS-30094
- ClinicalTrials.gov Identifier
- NCT06052267
- Study Status
- Recruiting
- Trial Condition(s)
- Asthma
- Interventions
- Drug: TEV-56248 | Drug: Albuterol sulfate
- EU CT Number
- 2023-505435-12-00
- Study Description
- The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). The secondary objectives are: To evaluate the efficacy of Fp/ABS low dose compared to ABS and the effect on systemic corticosteroid (SCS) exposure. To evaluate the safety and tolerability of Fp/ABS.The duration for each participant will be a minimum of 28 weeks including 2 weeks of screening, 2-4 weeks of run-in period and a double blind treatment period of minimum 24 weeks, however due to the event-driven nature of this study, the duration may range up to approximately 42 months depending on the timing when the participant was enrolled to the study, and when the study reaches its completion criteria.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 4 years and older
- Trial Duration
- August 30, 2023 – October 31, 2026
- Phase
- Phase 3